Double Victory! Onradivir Achieves Enrollment Completion in Two Pivotal Phase III Clinical Studies, Full-Age Protection on the Horizon!
Recently, following the successful inclusion of Raynovent's globally first and only RNA polymerase PB2 inhibitor anti-influenza new drug Onradivir (brand name:安睿威®) in the 2025 National Reimbursement Drug List (NRDL), the development of Onradivir has reached another exciting milestone! The company's two dosage forms—Onradivir tablets (adolescent indication) and Onradivir granules (pediatric indication)—have both completed enrollment in their Phase III registrational clinical studies, once again demonstrating and refreshing the "Raynovent Speed."
Under the guidance and leadership of Leading PIs Professor Jiemin Qu from Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (for tablets) and Professor Baoping Xu from Beijing Children's Hospital, Capital Medical University (for granules), with support from PIs and research teams at all participating centers, and through the collective efforts of all partners, the Raynovent team actively implemented the Group's strategy of "Innovation-led, Quality and Efficiency in Parallel." Seizing the influenza season window, the adolescent Phase III study for Onradivir tablets was completed in just one month, while the pediatric Phase III study for Onradivir granules was completed in merely half a month. This represents the most solid step forward toward our grand goal of providing superior treatment options for influenza patients across all age groups.
The successful advancement of the two pivotal Phase III studies for Onradivir tablets and granules epitomizes Raynovent's R&D system's efficient collaboration and courageous innovation. From strategic planning characterized by "scientific foresight and intelligent preemptive action," to execution-level "process optimization and extreme compression," to "precise empowerment and breakthrough" when facing bottlenecks—every step embodies the dedication and trust of all project members, collaborating researchers, and participating families.